A detailed history of Private Capital Group, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Private Capital Group, LLC holds 41 shares of PCRX stock, worth $680. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41
Previous 41 -0.0%
Holding current value
$680
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 21, 2022

BUY
$60.03 - $76.49 $540 - $688
9 Added 28.13%
41 $3,000
Q3 2021

Oct 13, 2021

BUY
$54.64 - $61.3 $710 - $796
13 Added 68.42%
32 $2,000
Q2 2021

Jul 26, 2021

SELL
$59.18 - $69.99 $236 - $279
-4 Reduced 17.39%
19 $1,000
Q1 2021

Apr 12, 2021

SELL
$59.31 - $78.82 $11,565 - $15,369
-195 Reduced 89.45%
23 $2,000
Q4 2020

Jan 26, 2021

BUY
$50.47 - $66.26 $3,129 - $4,108
62 Added 39.74%
218 $13,000
Q3 2020

Nov 12, 2020

BUY
$51.97 - $63.0 $8,107 - $9,828
156 New
156 $9,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $761M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.